Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring
- Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring
- 김광명; 김종호; 박형규; 김유진; 박경순; 남해연; 이슬기; 박재형; 박랑운; 김인산; 최귀원; 김상윤; 박기남; 권익찬
- Theragnosis; Chitosan nanoparticle; Paclitaxel; Tumor homing; Drug delivery; Non-invasive imaging
- Issue Date
- Journal of controlled release
- VOL 146, NO 2, 219-227
- Theragnostic multifunctional nanoparticles hold great promise in simultaneous diagnosis of disease, targeted
drug delivery with minimal toxicity, and monitoring of treatment. One of the current challenges in cancer
treatment is enhancing the tumor-specific targeting of both imaging probes and anticancer agents. Herein,
we report tumor-homing chitosan-based nanoparticles (CNPs) that simultaneously execute cancer diagnosis
and therapy (cancer theragnosis). These CNPs are unique for their three distinctive characteristics, such as
stability in serum, deformability, and rapid uptake by tumor cells. These properties are critical in increasing
their tumor targeting specificity and reducing their nonspecific uptake by normal tissues. To develop these
CNPs into novel theragnostic nanoparticles, we labeled them with Cy5.5, a near-infrared fluorescent (NIRF)
dye, for imaging and also loaded them with paclitaxel (PTX-CNPs), an anticancer drug, for cancer treatment.
Cy5.5 labeled PTX-CNPs exhibited significantly increased tumor-homing ability with low nonspecific uptake
by other tissues in SCC7 tumor-bearing mice. Theragnostic nanoparticles, Cy5.5 labeled PTX-CNPs, are highly
useful for simultaneous diagnosis of early-stage cancer and drug delivery.
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.